Announcement
06 Nov 2025
In November 2025, the United States government announced an agreement with Novo Nordisk to implement most-favoured-nation drug pricing for American patients. The agreement secured an exemption for Novo Nordisk from prospective tariffs on the pharmaceutical imports.
Source
Sign in to access
Number of interventions
4
0 certainly harmful
4 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 07 Nov 2025
Localisation, nes
On 6 November 2025, the U.S. Administration announced an agreement with Novo Nordisk. Under the agreement, Novo Nordisk will be exempt from future Section 232 tariffs on pharmaceutical products for th...
Sign in to see more
Updated: 07 Nov 2025
FDI: Financial incentive
On 6 November 2025, the U.S. Administration announced an agreement with Novo Nordisk. Under the agreement, Novo Nordisk committed to make investments in manufacturing in the United States. In return, ...
Sign in to see more
Updated: 07 Nov 2025
Tax or social insurance relief
On 6 November 2025, the U.S. Administration announced reaching an agreement with Novo Nordisk. Under the agreement, Novo Nordisk will be exempt from future Section 232 tariffs on pharmaceutical produc...
Sign in to see more
Updated: 07 Nov 2025
Import tariff
On 6 November 2025, the United States announced an agreement with Novo Nordisk providing the company with three years of tariff relief from the future Section 232 pharmaceutical tariffs. In exchange, ...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.